Ways and Means Committee, Finance Committee, Health Subcommittee, Energy and Commerce Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants. (Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 578.
Committee on Ways and Means discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5239-5243)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Motion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Finance.
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 578.
Committee on Ways and Means discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5239-5243)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Motion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Finance.
Congressional oversightDrug, alcohol, tobacco useDrug therapyDrug trafficking and controlled substancesGovernment studies and investigationsHealth care qualityHealth personnelHealth programs administration and fundingHome and outpatient careHospital careMedicareMental healthPerformance measurementPrescription drugsUser charges and fees
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act
USA115th CongressHR-5605| House
| Updated: 6/20/2018
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants. (Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 578.
Committee on Ways and Means discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5239-5243)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Motion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Finance.
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 578.
Committee on Ways and Means discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5239-5243)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Motion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Finance.
Congressional oversightDrug, alcohol, tobacco useDrug therapyDrug trafficking and controlled substancesGovernment studies and investigationsHealth care qualityHealth personnelHealth programs administration and fundingHome and outpatient careHospital careMedicareMental healthPerformance measurementPrescription drugsUser charges and fees